Department of Neurosurgery, University Hospital Bonn, University of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany; Department of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Str. 3, D-53121 Bonn, Germany.
Department of Neurosurgery, University Hospital Bonn, University of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany.
Cytokine. 2017 Sep;97:96-103. doi: 10.1016/j.cyto.2017.05.025. Epub 2017 Jun 10.
IL-23 and IL-17 are pro-inflammatory cytokines. IL-23 is secreted by activated macrophages and dendritic cells, while IL-17 by Th17 cells. Serum IL-23 and IL-17 are known to be elevated in numerous inflammatory diseases including neurodegenerative diseases. The role of serum IL-23 and IL-17 in aneurysmal subarachnoid hemorrhage (aSAH) has still not been investigated. The present work investigates the serum IL-23 and IL-17 levels and their association with post hemorrhagic complications and clinical outcome in patients with aSAH.
In this study, 80 patients with aSAH (Hunt and Hess grade I-V) were prospectively recruited. We enrolled 24 control patients with lumbar spinal stenosis. Peripheral venous blood was withdrawn from controls and from aSAH patients at day 1 and day 7, allowed to clot and centrifuged to obtain serum. Enzyme linked immunoassay kits were employed to quantify the serum levels of IL-23 and IL-17 by applying 50µL of serum samples. Post hemorrhagic complications and clinical outcome were documented prospectively from patient's hospital record.
Serum IL-23 and IL-17 levels were significantly elevated in aSAH patients at day 1 and day 7 (n=80) as compared to control patients (n=24). Further analysis after dichotomy of patients who suffered from post hemorrhagic complications including cerebral vasospasm, chronic hydrocephalus, seizures, cerebral ischemia, delayed neurological deficits showed differential correlations with different post hemorrhagic complications (Table 1). Serum IL-23 and IL-17 levels did not correlate with clinical outcome.
Serum IL-23 and IL-17 levels were elevated in patients with aSAH showing upregulation of IL-23/IL-17 inflammatory axis after aSAH. Serum IL-23 and IL-17 showed differential correlations with post hemorrhagic complications and no correlation with clinical outcome.
IL-23 和 IL-17 是促炎细胞因子。IL-23 由活化的巨噬细胞和树突状细胞分泌,而 IL-17 由 Th17 细胞分泌。已知在许多炎症性疾病中,包括神经退行性疾病,血清 IL-23 和 IL-17 会升高。血清 IL-23 和 IL-17 在颅内动脉瘤性蛛网膜下腔出血(aSAH)中的作用尚未得到研究。本研究调查了血清 IL-23 和 IL-17 水平及其与 aSAH 患者出血后并发症和临床结局的关系。
本研究前瞻性招募了 80 例 aSAH 患者(Hunt 和 Hess 分级 I-V)。我们招募了 24 例腰椎狭窄症的对照组患者。从对照组和 aSAH 患者中抽取外周静脉血,让其凝固并离心以获得血清。采用酶联免疫吸附试剂盒,通过应用 50µL 血清样本,定量血清中 IL-23 和 IL-17 的水平。从患者的住院病历中前瞻性记录出血后并发症和临床结局。
与对照组患者(n=24)相比,aSAH 患者在第 1 天和第 7 天(n=80)的血清 IL-23 和 IL-17 水平显著升高。进一步对患有出血后并发症(包括脑血管痉挛、慢性脑积水、癫痫、脑缺血、迟发性神经功能缺损)的患者进行二分法分析后,显示与不同出血后并发症的相关性存在差异(表 1)。血清 IL-23 和 IL-17 水平与临床结局无相关性。
aSAH 患者的血清 IL-23 和 IL-17 水平升高,表明 aSAH 后 IL-23/IL-17 炎症轴的上调。血清 IL-23 和 IL-17 与出血后并发症呈不同相关性,与临床结局无相关性。